Net costs, net QALYs gained, and cost per QALY gained as compared to no treatment programme for the 30% and 45% HCV prevalence scenarios and various optimisation programmes.

The optimal 10 year programme is determined for each scenario, and then costs and QALYs are calculated for a further 40 years (for a 50 year time horizon) in order to account for the onward prevention benefits of the treatment programme. Scenario A: minimising health service costs and HCV health utility losses (measured in monetarised QALY loss). Scenario B: minimising health service costs and HCV health utility losses with a final time prevalence target. Scenario C: minimising only health service costs with a final time prevalence target.
1Net costs = health care costs over 50 years with the 10 year treatment programme - health care costs over 50 years with no treatment. Health care costs are defined as programme (antiviral treatment and search) costs as well as HCV infection related costs.
2Net QALY gain = QALYs gained over 50 years with the 10 year treatment programme - QALYs gained over 50 years with no treatment.